EUTECNIQ Sciences

See every page on one mapArrow keys move through results · Enter opens · Esc closes

Investors · Appendix Primary sources Third-party estimates labeled Proposed company

Market and regulatory context

The sourced market, evidence and regulatory data behind the investment thesis: how large the U.S. botanical market is, how thin the evidence behind most products remains, why that gap exists and which 2025–2026 rules change it. The business plan is on the investment thesis page.

$13.23BUS retail sales of herbal supplements in 2024, a record (+5.4%)
60.2%of US adults used a dietary supplement in the past 30 days, August 2021–August 2023
739botanical INDs received by FDA, March 1984 to December 2020; about half had been withdrawn or terminated by December 2020
36.5%of FDA's 1,078 substantive responses to new dietary ingredient notifications were acknowledgments without objection, 1995–2020

HerbalGram 144 (2025), NBJ data; NCHS Data Brief 561 (May 2026); FDA CDER, "What is a Botanical Drug?" (Sep 3, 2026) and Park et al., Ther Innov Regul Sci 2025; FDA data obtained under FOIA, reported by Natural Products Insider (Dec 18, 2020).

Status. EUTECNIQ is a company in formation. It has no laboratory, hired staff, customers, data, patents or revenue. Everything it would do is a proposal. This page is information only and is not an offer of securities.

The gap

A large market, thin proof

US herbal supplement sales nearly doubled between 2015 and 2024, and six in ten US adults use a supplement. The evidence base has not kept pace. FDA has approved four botanical products as prescription drugs (2006–2023). Separately, it received 739 botanical investigational new drug applications from 1984 to 2020; the two counts cover different products and periods, so they are not an approval rate. About a third (36.5%) of FDA's substantive responses to new dietary ingredient notifications, 1995–2020, were acknowledgments without objection.

Safety signals point the same way. Herbal and dietary supplements were judged to have caused 15.5% of liver-injury cases in a US referral network, and EFSA was unable to identify a safe dose of the green tea catechin EGCG in supplements.

US herbal supplement sales reached $13.2 billion in 2024, nearly twice the 2015 levelNBJ data via HerbalGram
US retail sales of herbal supplements, billions of US dollars: 2015 6.922; 2019 9.530; 2020 11.168; 2021 12.241; 2022 12.018; 2023 12.551; 2024 13.231. Years 2016 to 2018 not shown.051015US$ billion, retail20152015: US$6.922 billion6.920162017201820192019: US$9.530 billion9.520202020: US$11.168 billion11.220212021: US$12.241 billion12.220222022: US$12.018 billion12.020232023: US$12.551 billion12.620242024: US$13.231 billion13.2– 2016 to 2018 not shown in this series2024: +5.4%, a recordUS retail sales of herbal supplements, billions of US dollars: 2015 6.922; 2019 9.530; 2020 11.168; 2021 12.241; 2022 12.018; 2023 12.551; 2024 13.231. Years 2016 to 2018 not shown.051015US$ billion, retail’152015: US$6.922 billion6.9’16’17’18’192019: US$9.530 billion’202020: US$11.168 billion11.2’212021: US$12.241 billion’222022: US$12.018 billion’232023: US$12.551 billion’242024: US$13.231 billion13.2– 2016–18 not shown
Show data
YearUS retail sales, US$ billionChange
20156.922—
20199.530—
202011.168+17.2%
202112.241+9.6%
202212.018−1.8%
202312.551+4.4%
202413.231+5.4%
All retail channels; excludes teas and cosmetics, includes CBD. In 2024 direct-to-consumer sales were $7.503 billion, natural and specialty $3.121 billion, mass market $2.607 billion. An ABC press release of Sept 12, 2024 misprints 2023 as $15.551 billion; the report gives $12.551 billion.Smith T, Lang C, Craft E. HerbalGram 2025;(144):46–69, Herb Market Report (Nutrition Business Journal data).
Most new-ingredient notifications historically drew an FDA objection; recent years cleared more oftenFDA data via trade press
Share of new dietary ingredient notifications acknowledged by FDA without objection, by fiscal year: FY18 44.7%, FY19 47.5%, FY20 37.2%, FY21 about 55%, FY22 71%, FY23 61%; 36.5% cumulative from 1995 to December 20200%25%50%75%100%Acknowledged without objectionFY18: 44.7% (17 of 38 responses)44.7%FY18FY19: 47.5% (19 of 40)47.5%FY19FY20: 37.2% (of 43 substantive responses)37.2%FY20FY21: 55% (about 55%)≈55%FY21FY22: 71% (30 of 42)71%FY22FY23: 61% (27 of 44)61%FY2336.5% cumulative,1995 to Dec 2020(1,078 responses)Share of new dietary ingredient notifications acknowledged by FDA without objection, by fiscal year: FY18 44.7%, FY19 47.5%, FY20 37.2%, FY21 about 55%, FY22 71%, FY23 61%; 36.5% cumulative from 1995 to December 20200%25%50%75%100%Acknowledged without objectionFY18: 44.7% (17 of 38 responses)44.7%FY18FY19: 47.5% (19 of 40)47.5%FY19FY20: 37.2% (of 43 substantive responses)37.2%FY20FY21: 55% (about 55%)≈55%FY21FY22: 71% (30 of 42)71%FY22FY23: 61% (27 of 44)61%FY2336.5% cumulative, 1995–2020
Text version

Share of NDINs acknowledged without objection: FY18 44.7% (17 of 38 responses); FY19 47.5% (19 of 40); FY20 37.2%; FY21 about 55%; FY22 71% (30 of 42); FY23 61% (27 of 44). Cumulative from 1995 to December 2020: 36.5% of 1,078 substantive responses to 1,166 notifications.

"Acknowledged without objection" is not an FDA approval. Fiscal years end September 30. Denominators are FDA responses issued in the year, which can include notifications filed the year before.Natural Products Insider / SupplySide Supplement Journal, reporting FDA data: Mar 26, 2019 (FY18); Feb 13, 2020 (FY19); Dec 18, 2020 (FY20 and cumulative, FOIA spreadsheet); Nov 8, 2022 (FY21, FY22); Dec 12, 2023 (FY23).
What the published record shows about evidence and safety for botanicals
FindingValueCaveat
Botanical products approved as prescription drugs (NDA or BLA)4: sinecatechins, crofelemer, birch triterpenes (NDAs); anacaulase-bcdb (BLA)Psyllium and witch hazel are separately marketed under OTC monographs
Botanical INDs received by FDA, March 1984–December 2020739 (254 oncology, 485 non-oncology)Other FDA counts differ by definition and date
Liver injury attributed to herbal and dietary supplements, DILIN 2004–2013130 of 839 cases (15.5%); share rose from 7% to 20%Eight referral centers; the cohort does not measure a national rate
EGCG from green tea in food supplements (EFSA, 2018)≥800 mg/day raised serum transaminases; no safe dose identifiedEU then limited EGCG to less than 800 mg per daily portion
St. John's wort for major depression (Cochrane, 29 trials, 5,489 patients)Extracts beat placebo and matched standard antidepressantsProducts "vary to a great extent"; trials from German-speaking countries were more favorable

FDA CDER, "What is a Botanical Drug?", content current as of Sep 3, 2026; Park JK et al., Ther Innov Regul Sci 2025 (FDA authors); Navarro VJ et al., Hepatology 2014;60:1399–1408; EFSA ANS Panel, EFSA J 2018;16(4):5239 and Commission Regulation (EU) 2022/2340; Linde K et al., Cochrane Database Syst Rev 2008, CD000448.

Root cause

Why the gap exists

The gap is structural. US law classifies a product by its intended use, so a supplement may not claim to treat disease. A naturally occurring constituent is not patent-eligible merely because it has been isolated, and supplements receive no data exclusivity, so a company that pays for a trial gains no exclusivity from its data. The drug route stays open, but a substance under substantial, public drug investigation cannot later enter the supplement channel unless it was sold as a supplement or food first.

The full argument is on the claims gap and in the course why supplements cannot make disease claims.

Five legal and scientific causes of the evidence gap
CauseRuleEffect on evidence
Intended use decides the categoryFD&C Act 201(g)(1), 21 U.S.C. 321(g)(1); structure/function statements under 21 U.S.C. 343(r)(6) and 21 CFR 101.93A supplement may describe effects on structure or function, with FDA's disclaimer, but not diagnose, treat, cure or prevent disease
No patent on a natural productAssociation for Molecular Pathology v. Myriad Genetics, 569 U.S. 576 (2013)A naturally occurring substance is not patent-eligible merely because it has been isolated; markedly different compositions, processes, formulations and uses can be
No data exclusivity for supplements5-year new chemical entity and 3-year new clinical investigation exclusivity apply to approved drugs (21 CFR 314.108)Clinical data paid for by a supplement company give it no period of market protection
The first lawful use decides the channel21 U.S.C. 321(ff)(3)(B)An article authorized for investigation as a new drug, with substantial public clinical investigations, cannot later become a supplement unless first marketed as a supplement or food
Botanical mixtures are hard to make consistentFDA Botanical Drug Development Guidance (December 2016)FDA reviewers attribute the low yield of botanical INDs to chemistry, manufacturing and controls (batch consistency) and to efficacy

21 U.S.C. 321, 343(r)(6) (U.S. Code, Cornell LII); 21 CFR 101.93 and 314.108 (eCFR); 569 U.S. 576 (2013); Park JK et al., Ther Innov Regul Sci 2025. Not legal advice.

Timing

Why now

Four regulatory dates fall between August and December 2026. FDA has finalized what an NDI notification must show about identity and safety, proposed making GRAS notification mandatory and asked for comment on advancing botanical drugs. Internationally, WHO adopted a ten-year traditional medicine strategy in 2025. Each raises the value of documented identity, safety and process records.

Five of seven events fall between December 2025 and December 2026Regulation and policy
Seven dated events from May 2025 to July 2028 on a time axis; five fall between December 2025 and December 2026; the dashed line marks October 28, 2026202520262027202820291. WHO strategy1WHO strategy2. WHO summit2WHO summit3. GRAS notification proposed34. FDA botanical drug RFI45. NDI guidance final56. GRAS comments close67. FSMA 204 compliance7FSMA 204 complianceOct 28, 2026Aug–Dec 2026Numbers match the table below. Shaded band: four events within five months.Seven dated events from May 2025 to July 2028 on a vertical time axis; the dashed line marks October 28, 2026202520262027202820291. WHO strategy1WHO strategy2. WHO summit2WHO summit3. GRAS notification proposed3GRAS notification proposed4. FDA botanical drug RFI4FDA botanical drug RFI5. NDI guidance final5NDI guidance final6. GRAS comments close6GRAS comments close7. FSMA 204 compliance7FSMA 204 complianceOct 28, 2026Numbers match the table below.
Dates from the Federal Register, FDA and WHO documents listed in the table below.
Seven dated regulatory and policy events
# and dateEventStatus and what it changes
1 · May 27, 2025WHO Traditional Medicine Strategy 2025–2034 adopted by the 78th World Health AssemblyAdopted; sets a ten-year agenda for evidence, regulation and integration
2 · Dec 17–19, 20252nd WHO Global Summit on Traditional Medicine, New DelhiHeld
3 · Aug 11, 2026FDA proposed rule "Substances Generally Recognized as Safe" (91 FR 51834)Proposed Mandatory GRAS notification; FDA estimates about 180 hours per notice. GRAS applies to food use; a supplement ingredient follows the dietary-ingredient and NDI rules instead.
4 · Sep 4, 2026FDA request for information, "Advancing Development of Botanical Drug Products" (91 FR 56887)Comment period closed Nov 3, 2026
5 · Oct 19, 2026FDA final guidance on identity and safety information in NDI notifications (91 FR 66336, Oct 20)Final guidance What makes an ingredient "new" remains in draft
6 · Dec 9, 2026Comment deadline on the GRAS proposalOpen
7 · Jul 20, 2028FSMA 204 food traceability compliance date, moved from Jan 20, 2026 (Pub. L. 119-37)Applies only to foods on the Food Traceability List

WHO, WHA78 document A78/14 and news release of Nov 14, 2025; Federal Register 91 FR 51834 (Aug 11, 2026; docket FDA-2025-N-3262), 91 FR 56887 (Sep 4, 2026; docket FDA-2026-N-9550), 91 FR 66336 (Oct 20, 2026; doc 2026-21453); FDA, FSMA final rule on additional traceability records (content current as of Oct 8, 2026). See also NDI notifications and GRAS and food ingredients.

Market context

Market context

The anchor is the US herbal series above: retail-sales estimates with a stated method. Global supplement forecasts are estimates, and one publisher's own releases disagree, so they appear here only as a range. The longer-term base is wide: traditional medicine is used across most WHO Member States, tens of thousands of plant species have documented medicinal use, and natural products remain a steady source of new drugs.

Market and resource context with source and status
MeasureValueSourceStatus
US herbal supplement retail sales, 2024$13.231 billion (+5.4%)NBJ data, HerbalGram 144 (2025)Measured estimate
Global dietary supplements, projected 2033$393.56–431.69 billion; CAGR 8.1–9.5%Grand View Research releases: $414.52 billion at 8.9% CAGR (reported Dec 1, 2025); $393.56 billion at 8.1% (2026); its February 2026 release page shows $393.56 billion in the title and $431.69 billion at 9.5% in the textEstimate; releases disagree
US adults using any supplement60.2% (Aug 2021–Aug 2023), up from 53.8% in 2013–2014NCHS Data Brief 561, NHANESSurvey
Countries reporting use of traditional medicine170 WHO Member StatesWHO, Nov 14, 2025Primary
Documented medicinal plant species25,791; 723 of 5,411 assessed (13%) threatenedKew, State of the World's Plants and Fungi 2020Primary
New approved drugs related to natural products, 1981–201932 ± 9% a year, of 1,881 approvalsNewman and Cragg, J Nat Prod 2020Peer-reviewed

Market sizes for botanical extracts, testing services and contract research could not be verified and are not shown. More data: market data and global trade.

Industry transactions

What buyers have paid in this industry

Large food, flavor and nutrition companies have bought supplement and botanical-ingredient businesses at disclosed prices. These are other companies' transactions, listed because their terms are public. They are market context, not comparables for EUTECNIQ, a forecast or a statement about any exit.

Four disclosed industry transactions
Buyer and targetDateDisclosed valueDisclosed metric
Nestlé – Atrium InnovationsAnnounced Dec 5, 2017US$2.3 billion, cashAtrium 2017 sales expected at almost US$700 million
Nestlé – The Bountiful Company, core brandsApr 30, 2021US$5.75 billion3.1× net sales and 16.8× EBITDA; net sales US$1.87 billion in the 12 months to Mar 31, 2021. In July 2025 Nestlé began a strategic review of the supplement brands from this deal
Givaudan – NaturexCompleted Jun 4, 2018€522 million for 40.5%€135 per share; Givaudan stated it would make a mandatory cash offer for the remaining shares at the same price
IFF – FrutaromAnnounced May 7, 2018≈US$7.1 billion incl. net debt20.3× Frutarom's expected 2018 EBITDA

Nestlé press releases of Dec 5, 2017 and Apr 30, 2021; FoodNavigator, Jul 25, 2025; Givaudan media release of Jun 4, 2018; IFF Form 8-K, Exhibit 99.2, May 7, 2018. See also the competitor comparison.

Request investor materials

Introductions for qualified parties. Information only; not an offer of securities.

Health information notice. These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease, and nothing here is medical advice.

Read the full notice

The information is for general education only. It does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed. Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to start a development project?

Tell us about an ingredient you want to specify, verify or license. Questions? Email [email protected]